Advances in the treatment of primary biliary cholangitis
10.3760/cma.j.issn.1007-3418.2017.11.002
- VernacularTitle: 原发性胆汁性胆管炎治疗进展
- Author:
Yanmei LI
1
;
Qixia WANG
;
Xiong MA
Author Information
1. Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Disease, Shanghai 200001, China
- Publication Type:Journal Article
- Keywords:
Thrapy;
Primary biliary cholangitis;
Ursodeoxycholic acid;
Obeticholic acid
- From:
Chinese Journal of Hepatology
2017;25(11):805-809
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cholangitis (PBC) is an autoimmune liver disease mainly involving intrahepatic interlobular bile ducts and can progress to liver fibrosis, liver cirrhosis, and even liver failure. Ursodeoxycholic acid (UDCA) is the first-line therapeutic drug for PBC and can delay disease progression, but as high as 40% of patients have suboptimal response to UDCA. Obeticholic acid, a farnesoid X receptor agonist, has been approved by FDA in May 2016 for patients who have no response to UDCA treatment or cannot tolerate such treatment. Other drugs such as fibrates, glucocorticoids, immunosuppressants, biological agents, and mesenchymal stem cells are gradually used in clinical practice and bring new hope to patients with refractory PBC.
